Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Horizon Pharma plc's Stock Slumped in April

By George Budwell - May 5, 2016 at 10:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's stock slumped last month on weaker than expected guidance for the first half of 2016.

HZNP Chart

What: Shares of Horizon Pharma (HZNP 1.35%) dropped by 11.5% in April, according to data from S&P Global Market Intelligence. The drugmaker's monthly decline primarily stemmed from its updated annual guidance that hit the Street last month, and subsequently fell below analysts' expectations in terms of net product sales for the first and second quarter of 2016. That said, Horizon did reaffirm its 2016 annual sales guidance of $1.025 billion to $1.05 billion, implying that product sales should pick up in the second half of the year. 

So what: Horizon's updated, and somewhat disappointing, annual guidance couldn't have come at a worse time. After all, market sentiment has been steadily turning against the specialty pharmacy model due to Valeant Pharmaceuticals' (BHC 2.03%) spectacular implosion, combined with the heated political debate regarding branded drug pricing schemes in the United States right now. 

Now what: Horizon is struggling to throw off the impression that it's basically Valeant Lite, especially after the company disclosed that it had received a subpoena from the U.S. Attorney's office for the Southern District of New York requesting information related to its patient assistance programs. Some critics claim that Horizon's patient assistance programs are little more than a tactic to lower the barriers to reimbursement, allowing the company to charge exorbitant prices for certain medicines. As a reminder, Valeant was investigated by the same office for similar practices last year, leading the drugmaker to cut ties with the specialty pharmacy Philidor.

Horizon's management has thus been attempting to pivot the company more toward an orphan drug model -- a business model that rarely garners stinging criticism from payers or politicians. However, until the smoke clears, investors might be best served by remaining on the sidelines with this pharma stock, despite the drugmaker's recent upswing in net product sales across across its product portfolio.

Data source: Horizon Pharma.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$80.84 (1.35%) $1.08
Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$8.53 (2.03%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.